-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
All five products submitted by Shijiazhuang Fourth Pharmaceutical Group for the 8th round of national centralized procurement are expected to win bids.
Category:
Time：2023-03-30
On March 29, the eighth round of national centralized bulk procurement of pharmaceutical products—highly anticipated by pharmaceutical companies and society—was opened for bidding in Lingshui, Hainan. Shijiazhuang Fourth Pharmaceutical Group’s five new products—aggrastat injection, ornidazole injection, metronidazole injection, felodipine II sustained-release tablets, and methylcobalamin injection—covering a total of seven specifications, were all preliminarily awarded contracts.
On March 29, the eighth round of national centralized bulk procurement of pharmaceutical products—highly anticipated by pharmaceutical companies and society—began bidding in Lingshui, Hainan. Shijiazhuang Four Pharmaceutical Group’s five new products—aggrastat injection, ornidazole injection, metronidazole injection, felodipine II sustained-release tablets, and methylcobalamin injection—covering a total of seven specifications, were all preliminarily awarded contracts.
It is reported that Shijiazhuang Fourth Pharmaceutical, with its strong overall advantages, has won the bid for Oronazole Injection (3 ml: 0.5 g; 6 mg: 1 g) in first place, and will exclusively supply four provinces—Jiangsu, Hebei, Jiangxi, and Heilongjiang. Felodipine/Felodipine II sustained-release tablets (5 mg) have been awarded second place and will be exclusively supplied to five provinces and cities—Zhejiang, Yunnan, Chongqing, Shaanxi, and Tibet. Mecobalamin Injection (1 ml: 0.5 mg), also awarded second place, will be exclusively supplied to six provinces—Zhejiang, Hunan, Hebei, Heilongjiang, Inner Mongolia, and Liaoning. Metronidazole Injection (100 ml: 0.5 g; 250 ml: 1.25 g), awarded third place, will be exclusively supplied to three provinces—Guangxi, Hebei, and Fujian. Aggrastat Injection (2 ml: 10 mg), awarded fifth place, will be exclusively supplied to three provinces—Heilongjiang, Yunnan, and Hainan.
In recent years, Shijiazhuang No.4 Pharmaceutical Group has closely aligned itself with the strategic needs of building a Healthy China. Supported by a comprehensive package of national, provincial, and municipal policies aimed at benefiting enterprises and fostering industrial development, the group has taken innovation-driven development as its guiding principle and actively implemented a “API + Finished Dosage Form” growth strategy. Leveraging an innovative mechanism that integrates industry, academia, research, and application, the group is focusing on new growth areas, building new competitive advantages, creating new development patterns, generating new momentum, and seizing new opportunities.
“Increasingly abundant innovation achievements provide robust support and guarantees for enterprises to participate in market competition, offering a stronger backing and a powerful engine for high-quality enterprise development,” said a relevant official from the group. Over the past two years, Shijiazhuang Sihua Pharmaceutical Group has been strategically aligning its innovation chain with the industrial chain, comprehensively promoting the research and development of high-end, complex generic drugs, innovative pharmaceuticals, specialty active pharmaceutical ingredients, and products that have undergone consistency evaluations. The group has accelerated its efforts in key therapeutic areas such as antiviral, antibacterial, cough-relief and expectorant, anti-tumor, nervous system, cardiovascular, digestive, and anesthetic treatments, yielding substantial and well-accumulated R&D results. Currently, the group has nearly 200 projects under development and more than 100 new products awaiting approval, creating a new paradigm of product iteration—“developing a batch, reserving a batch, and commercializing a batch.” In 2022, the group obtained a total of 37 product approvals, ranking among the top in China’s industry in terms of both the efficiency of specialty generic drug R&D and the number of applications submitted. As of now, Shijiazhuang Sihua Pharmaceutical has achieved a cumulative total of 43 varieties and 55 specifications through consistency evaluations, giving it a significant advantage and creating ample room for optimizing product portfolios, gaining entry into national centralized procurement, and enhancing product market competitiveness.
Relevant officials from the group stated that winning this bid will help enhance product market accessibility, accelerate the development and launch of new products into the market, and enable large-scale sales. This will have a positive impact on increasing market share, boosting regional sales, and strengthening market influence.
It is reported that the eighth round of nationally organized centralized drug procurement involved 366 products from 251 companies. Among them, 252 products from 174 companies were shortlisted as potential winners, representing a winning bid rate of approximately 70% among participating companies. On average, 6.5 companies won bids for each product, further enhancing both supply diversity and stability. The National Healthcare Security Administration, together with relevant departments, will guide local authorities and winning companies to ensure smooth implementation of the procurement results, guaranteeing that patients can access the reduced-price winning products starting from July 2023.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license